Prevalence of Fabry Disease among Patients with Parkinson’s Disease

Table 1

Characteristics of the PD population (N = 236).

	Mean ± SD (N, %)	Range
Age (years)	68.9 ± 8.9	33–88
Gender
Male	130 (55.1%)
Female	106 (44.9%)
Age of onset	61.13 ± 10.35	27–85
Disease duration	7.77 ± 5.35	0–30
MDS-UPDRS part III score	27.58 ± 13.35	3–80
Presence of GLA gene mutations (N = 126) c.937G > T, p. (Asp313Tyr)	4 (3.17%)
alpha-Galactosidase level in men (N = 129); <15.3 μmol/L/h (pathological); Pathological level of AGLA	22.40 ± 7.57; 20 (15%); 12,25 ± 2.51	5.3–57.2; 5.3–15.2
Lyso-Gb3 level in men; > 1.8 ng/ml (pathological)	1,23 ± 0,22; 0	0.9–1.7

MDS-UPDRS: Movement Disorder Society-Unified Parkinson’s Disease Rating Scale.